{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:23:08Z","timestamp":1784697788715,"version":"3.55.0"},"reference-count":86,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Gastric cancer currently has the third highest mortality rate worldwide among cancer types. Despite gradual declines in mortality rates attributed to improvements in early detection and treatment, outcomes for advanced-stage disease are still poor. The identification of new biomarkers such as fibroblast growth factor receptor 2 (FGFR2) has opened new pathways for directed therapy in gastric cancer. Objective: This review aims to synthesize the current evidence on the role of FGFR2 in gastric cancer, focusing on its biological function and oncogenic mechanisms, diagnostic and prognostic modification, therapeutic targeting, and possible roadblocks in clinical application. Methods: A comprehensive literature search was conducted, selecting studies published between 2015 and 2025 using the MeSH terms \u201cFGFR2 protein, human\u201d [Supplementary Concept]) AND \u201cStomach Neoplasms\u201d. Articles were screened based on relevance to gastric cancer, language (English), and availability of full text, yielding a final selection of 75 studies, including preclinical research, clinical trials, and reviews. Findings: We compiled and reported the evidence on FGFR2 detection methods, intra-tumoral heterogeneity of FGFR2 expression, effects of FGFR2 expression on prognosis, current therapy options targeting FGFR2, and challenges in pursuing this modality of treatment. Conclusion: FGFR2 represents a promising biomarker and therapeutic target in gastric cancer.<\/jats:p>","DOI":"10.3390\/medicina61111890","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:14:02Z","timestamp":1761182042000},"page":"1890","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Role of FGFR2 as a Novel Biomarker for Treatment of Gastric Cancer\u2014A Literature Review"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2705-6675","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Lages dos Santos","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Anatomia Patol\u00f3gica, Unidade Local de Sa\u00fade de Gaia e Espinho, 4434-502 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7202-8059","authenticated-orcid":false,"given":"Rui","family":"Caetano Oliveira","sequence":"additional","affiliation":[{"name":"Centro de Anatomia Patol\u00f3gica Germano de Sousa, 3030-075 Coimbra, Portugal"},{"name":"Instituto de Histologia e Embriologia, Faculdade de Medicina da Universidade de Coimbra, 3004-528 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5274-4114","authenticated-orcid":false,"given":"Jo\u00e3o Martins","family":"Gama","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Anatomia Patol\u00f3gica, Unidade Local de Sa\u00fade de Coimbra, 3004-561 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zhang, H., Yang, W., Tan, X., He, W., Zhao, L., Liu, H., and Li, G. (2024). Long-term relative survival of patients with gastric cancer from a large-scale cohort: A period-analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-13141-5"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sato, Y., Okamoto, K., Kawano, Y., Kasai, A., Kawaguchi, T., Sagawa, T., Sogabe, M., Miyamoto, H., and Takayama, T. (2023). Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives. J. Clin. Med., 12.","DOI":"10.3390\/jcm12144646"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s10147-024-02521-3","article-title":"New therapeutic target molecules for gastric and gastroesophageal junction cancer","volume":"29","author":"Kawakami","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5230\/jgc.2024.24.e6","article-title":"Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond","volume":"24","author":"Kim","year":"2024","journal-title":"J. Gastric Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/cco-23-120","article-title":"How to use anti-PD-1 therapy in gastric cancer: The approach in the United States","volume":"13","author":"Ilson","year":"2024","journal-title":"Chin. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"oyae238","DOI":"10.1093\/oncolo\/oyae238","article-title":"Clinicopathologic and molecular characterization of stages II\u2013IV gastric cancer with Claudin 18.2 expression","volume":"30","author":"Kwak","year":"2025","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","article-title":"HER2 testing in gastric cancer: An update","volume":"22","author":"Lucas","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s00018-018-2906-9","article-title":"Microsatellite instability in gastric cancer: Molecular bases, clinical perspectives, and new treatment approaches","volume":"75","author":"Ratti","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5230\/jgc.2025.25.e4","article-title":"PD-L1 as a Biomarker in Gastric Cancer Immunotherapy","volume":"25","author":"Cho","year":"2025","journal-title":"J. Gastric Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zhang, M., Dong, Y., Liu, H., Wang, Y., Zhao, S., Xuan, Q., and Zhang, Q. (2016). The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: A meta-analysis of 10 studies with 1,901 patients. Sci. Rep., 6.","DOI":"10.1038\/srep37933"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yao, J., Sun, Q., Wu, H., Zhao, X., Yang, P., Wang, X., Wang, X., Gu, M., Li, J., and Zheng, Y. (2025). Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1567308"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17588359241247023","DOI":"10.1177\/17588359241247023","article-title":"Navigating uncharted territory: A case report and literature review on the remarkable response to personalized crizotinib containing combinational therapy in a pazopanib refractory patient with novel alterations","volume":"16","author":"Tokat","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0092-8674(00)80851-X","article-title":"Crystal Structures of Two FGF-FGFR Complexes Reveal the Determinants of Ligand-Receptor Specificity","volume":"101","author":"Plotnikov","year":"2000","journal-title":"Cell"},{"key":"ref_17","unstructured":"Katoh, M. (2025, March 22). FGFR2 (Fibroblast Growth Factor Receptor 2). Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available online: https:\/\/atlasgeneticsoncology.org\/gene\/40570\/fgfr2-(fibroblast-growth-factor-receptor-2)."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-022-05066-5","article-title":"Truncated FGFR2 is a clinically actionable oncogene in multiple cancers","volume":"608","author":"Zingg","year":"2022","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2400710","DOI":"10.1200\/PO-24-00710","article-title":"Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial","volume":"9","author":"Rha","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"a001495","DOI":"10.1101\/mcs.a001495","article-title":"FGFR2 amplification in colorectal adenocarcinoma","volume":"3","author":"Carter","year":"2017","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-07-5229","article-title":"FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival","volume":"68","author":"Kunii","year":"2008","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/modpathol.2016.96","article-title":"FGFR2 in gastric cancer: Protein overexpression predicts gene amplification and high H-index predicts poor survival","volume":"29","author":"Ahn","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"15014","DOI":"10.18632\/oncotarget.14788","article-title":"Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion","volume":"8","author":"Ahn","year":"2017","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1309\/AJCPNFLSMWWPP8DR","article-title":"FGFR2 assessment in gastric cancer using quantitative real-time polymerase chain reaction, fluorescent in Situ Hybridization, and Immunohistochemistry","volume":"143","author":"Park","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/jjco\/hyab104","article-title":"Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer","volume":"51","author":"Minashi","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10120-017-0758-x","article-title":"In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients","volume":"21","author":"Kuboki","year":"2018","journal-title":"Gastric Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1111\/cas.14654","article-title":"Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor","volume":"111","author":"Kuroda","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-21-1414","article-title":"Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer","volume":"27","author":"Jogo","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/oncolo\/oyae061","article-title":"Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers","volume":"29","author":"Shariff","year":"2024","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"87095","DOI":"10.18632\/oncotarget.19764","article-title":"Identification and validation of FGFR2 peptide for detection of early Barrett\u2019s neoplasia","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"ref_32","first-page":"5055","article-title":"Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance","volume":"35","author":"Shoji","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lau, D.K., Collin, J.P., and Mariadason, J.M. (2024). Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer. Biomedicines, 12.","DOI":"10.3390\/biomedicines12051117"},{"key":"ref_34","first-page":"3893","article-title":"Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing","volume":"11","author":"Gu","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.2147\/OTT.S111778","article-title":"The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: A retrospective study","volume":"9","author":"Jia","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10120-014-0360-4","article-title":"Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma","volume":"18","author":"Nagatsuma","year":"2015","journal-title":"Gastric Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Byeon, S., Jung, J., Kim, S.T., Kim, K.M., and Lee, J. (2023). Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer. Biomedicines, 11.","DOI":"10.3390\/biomedicines11123172"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"28670","DOI":"10.18632\/oncotarget.8764","article-title":"A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth","volume":"7","author":"Park","year":"2016","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Tajirika, T., Tokumaru, Y., Taniguchi, K., Sugito, N., Matsuhashi, N., Futamura, M., Yanagihara, K., Akao, Y., and Yoshida, K. (2018). DEAD-box protein RNA-helicase DDX6 regulates the expression of HER2 and FGFR2 at the post-transcriptional step in gastric cancer cells. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19072005"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Aleyasin, S.A., Moradi, A., Abolhasani, N., and Abdollahi, M. (2024). Investigating FGFR2 gene as a blood-based epigenetic biomarker in gastric cancer. Mol. Biol. Rep., 51.","DOI":"10.1007\/s11033-023-09082-0"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Teles, S.P., Oliveira, P., Ferreira, M., Carvalho, J., Ferreira, P., and Oliveira, C. (2020). Integrated analysis of structural variation and rna expression of fgfr2 and its splicing modulator esrp1 highlight the esrp1amp-fgfr2norm-fgfr2-iiichigh axis in diffuse gastric cancer. Cancers, 12.","DOI":"10.3390\/cancers12010070"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2741\/4609","article-title":"Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells","volume":"23","author":"Ishiwata","year":"2018","journal-title":"Front. Biosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1007\/s00432-022-04460-w","article-title":"FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract","volume":"149","author":"Albin","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s10120-025-01611-z","article-title":"Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer","volume":"28","author":"Lee","year":"2025","journal-title":"Gastric Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ye, P., Zhang, M., Fan, S., Zhang, T., Fu, H., Su, X., Gavine, P.R., Liu, Q., and Yin, X. (2015). Intra-tumoral heterogeneity of HER2, FGFR2, cMET and ATM in gastric cancer: Optimizing personalized healthcare through innovative pathological and statistical analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143207"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3892\/ol.2016.5386","article-title":"Molecular heterogeneity in the novel fusion gene APIP-FGFR2: Diversity of genomic breakpoints in gastric cancer with high-level amplifications at 11p13 and 10q26","volume":"13","author":"Okuda","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9714570","DOI":"10.1155\/2022\/9714570","article-title":"Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing","volume":"2022","author":"Hyung","year":"2022","journal-title":"J. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12957-016-1081-4","article-title":"Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer","volume":"15","author":"Inokuchi","year":"2017","journal-title":"World J. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Liu, G., Xiong, D., Xiao, R., and Huang, Z. (2017). Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis. Tumor Biol., 39.","DOI":"10.1177\/1010428317707424"},{"key":"ref_50","first-page":"1853","article-title":"Prognostic relevance of FGFR2 expression in stage II\/III gastric cancer with curative resection and S-1 chemotherapy","volume":"15","author":"Hosoda","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"viii218","DOI":"10.1093\/annonc\/mdy282.031","article-title":"The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine-based chemotherapy","volume":"29","author":"Skupinska","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.7150\/jca.29184","article-title":"Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: A meta-analysis and systemic review","volume":"10","author":"Kim","year":"2019","journal-title":"J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Schrumpf, T., Behrens, H.M., Haag, J., Kr\u00fcger, S., and R\u00f6cken, C. (2022). FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264011"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3892\/ijo.2017.3927","article-title":"FGF7\/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1","volume":"50","author":"Huang","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1159\/000494590","article-title":"FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway","volume":"50","author":"Huang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12967-021-03079-8","article-title":"FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma","volume":"19","author":"Wang","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kim, H., Park, S., Kang, S.Y., Ahn, S., and Kim, K.M. (2022). Peritoneal Seeding Is More Common in Gastric Cancer Patients with FGFR2 Amplification or High Tumor Mutation Burden. Diagnostics, 12.","DOI":"10.3390\/diagnostics12102355"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Huang, Y.C., Chen, W.C., Yu, C.L., Chang, T.K., I-Chin Wei, A., Chang, T.M., Liu, J.F., and Wang, S.W. (2023). FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression. Biochem. Pharmacol., 218.","DOI":"10.1016\/j.bcp.2023.115853"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.3390\/curroncol31080321","article-title":"Deciphering the FGFR2 Code: Innovative Targets in Gastric Cancer Therapy","volume":"31","author":"Tojjari","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00432-016-2143-2","article-title":"Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)","volume":"142","author":"Kim","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"152878","DOI":"10.1016\/j.prp.2020.152878","article-title":"High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers","volume":"216","author":"Hur","year":"2020","journal-title":"Pathol. Res. Pract."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"293","DOI":"10.21873\/cdp.10107","article-title":"Intra-tumoral FGFR2 Expression Predicts Prognosis and Chemotherapy Response in Advanced HER2-positive Gastric Cancer Patients","volume":"2","author":"Nakamura","year":"2022","journal-title":"Cancer Diagn. Progn."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"33844","DOI":"10.18632\/oncotarget.12953","article-title":"Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers","volume":"8","author":"Seo","year":"2017","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3892\/ol.2015.3601","article-title":"Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts","volume":"10","author":"Liu","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.tranon.2017.03.001","article-title":"Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2\u2013Amplified Gastric Cancer Patient\u2013Derived Cell Model","volume":"10","author":"Jang","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-15-1246","article-title":"High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial","volume":"6","author":"Pearson","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/annonc\/mdx107","article-title":"A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification","volume":"28","author":"Bang","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/cas.15486","article-title":"Phase I study of the irreversible fibroblast growth factor receptor 1\u20134 inhibitor futibatinib in Japanese patients with advanced solid tumors","volume":"114","author":"Doi","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/oncolo\/oyad149","article-title":"Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors","volume":"28","author":"Javle","year":"2023","journal-title":"Oncologist"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"115262","DOI":"10.1016\/j.ejca.2025.115262","article-title":"Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications","volume":"218","author":"Satoh","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40261-022-01183-1","article-title":"Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports","volume":"42","author":"Quinzii","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1158\/2767-9764.CRC-24-0137","article-title":"A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2\/3-driven Solid Tumors","volume":"4","author":"Garmezy","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S858","DOI":"10.1016\/j.annonc.2023.09.1439","article-title":"Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification","volume":"34","author":"Yuan","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e70091","DOI":"10.1111\/cts.70091","article-title":"Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification","volume":"17","author":"Yuan","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s13691-024-00669-3","article-title":"A case of treatment-resistant advanced gastric cancer with FGFR2 gene alteration successfully treated with pemigatinib","volume":"13","author":"Shinomiya","year":"2024","journal-title":"Int. Cancer Conf. J."},{"key":"ref_77","unstructured":"Tucker, N. (2025, August 07). FDA Grants Breakthrough Therapy Designation to Bemarituzumab for Select FGFR2b+\/HER2\u2212 Advanced Gastric and GEJ Cancers. Targeted Oncology. Available online: https:\/\/www.targetedonc.com\/view\/fda-grants-breakthrough-therapy-designation-to-bemarituzumab-for-select-fgfr2b-her2--advanced-gastric-and-gej-cancers."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1981202","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"mAbs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: Final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): A randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2147\/OTT.S282718","article-title":"Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments","volume":"15","author":"Gordon","year":"2022","journal-title":"OncoTargets Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/1535-7163.MCT-17-0367","article-title":"Acquired resistance to FGFR inhibitor in diffuse-type gastric cancer through an AKT-independent PKC-mediated phosphorylation of GSK3\u03b2","volume":"17","author":"Lau","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41389-019-0145-z","article-title":"A functional CRISPR\/Cas9 screen identifies kinases that modulate FGFR inhibitor response in gastric cancer","volume":"8","author":"Chen","year":"2019","journal-title":"Oncogenesis"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1158\/1535-7163.MCT-17-1022","article-title":"Acquired JHDM1D-BRAF fusion confers resistance to FGFR inhibition in FGFR2-amplified gastric cancer","volume":"17","author":"Sase","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_85","first-page":"1511","article-title":"Diffuse-type gastric cancer cells switch their driver pathways from FGFR2 signaling to SDF1\/CXCR4 axis in hypoxic tumor microenvironments","volume":"36","author":"Kinoshita","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Watson, A.S., Le, C., Wertheimer, A., Escobedo, S., So, L., Siddegowda, B.B., Palting, J., Marion, S., Stratton, S.P., and Aggeler, B. (Arch. Pathol. Lab. Med., 2025). Precision Detection of FGFR2b Protein Expression in Solid Tumors: A Comprehensive Assessment of Staining Parameters via Automated Immunohistochemistry, Arch. Pathol. Lab. Med., in press.","DOI":"10.5858\/arpa.2024-0497-OA"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1890\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:06:07Z","timestamp":1761185167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":86,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61111890"],"URL":"https:\/\/doi.org\/10.3390\/medicina61111890","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]}}}